Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nidal Al-Huniti

Showing results (11-20 of 52) with videos related to

Pageof 6
Sort By:
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|June 7, 2006
Hypercholesterolemia is a potential risk factor for asthmaBaha Al-Shawwa, Nidal Al-Huniti, Gregory Titus, et al.
Clinical Pharmacokinetics|December 31, 2016
Clinical Pharmacokinetics and Pharmacodynamics of Naloxegol, a Peripherally Acting µ-Opioid Receptor AntagonistKhanh Bui, Diansong Zhou, Hongmei Xu, et al.
Journal of Clinical Pharmacology|December 19, 2015
Effects of CYP3A Modulators on the Pharmacokinetics of NaloxegolKhanh Bui, Diansong Zhou, Mark Sostek, et al.
Cancer Chemotherapy and Pharmacology|April 26, 2019
Resistance models to EGFR inhibition and chemotherapy in non-small cell lung cancer via analysis of tumour size dynamicsHitesh B Mistry, Gabriel Helmlinger, Nidal Al-Huniti, et al.
British Journal of Clinical Pharmacology|August 29, 2015
Population pharmacokinetics of naloxegol in a population of 1247 healthy subjects and patientsNidal Al-Huniti, Sunny Chapel, Hongmei Xu, et al.
Journal of Clinical Pharmacology|December 2, 2017
Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive MetabolizersYingxue Chen, Diansong Zhou, Weifeng Tang, et al.
Journal of Clinical Pharmacology|December 3, 2015
Population Pharmacokinetic and Pharmacodynamic Modeling of AZD4901 and Simulation to Support Dose Selection for the Phase 2a StudyHongmei Xu, Jianguo Li, Lorraine Webber, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 29, 2021
Population pharmacokinetics and exposure-response modeling for evinacumab in homozygous familial hypercholesterolemiaXia Pu, Mark Sale, Feng Yang, et al.
Basic & Clinical Pharmacology & Toxicology|February 11, 2019
Physiologically based pharmacokinetic modelling to predict exposure differences in healthy volunteers and subjects with renal impairment: Ceftazidime case studyLi Zhou, Xiao Tong, Pradeep Sharma, et al.
Pharmaceutical Statistics|August 27, 2019
Optimal designs for regional bridging studies using the Bayesian power prior methodMario Nagase, Shinya Ueda, Mitsuo Higashimori, et al.
Pageof 6

Showing results (11-20 of 52) with videos related to

Sort By:
Pageof 6
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|June 7, 2006
Hypercholesterolemia is a potential risk factor for asthmaBaha Al-Shawwa, Nidal Al-Huniti, Gregory Titus, et al.
Clinical Pharmacokinetics|December 31, 2016
Clinical Pharmacokinetics and Pharmacodynamics of Naloxegol, a Peripherally Acting µ-Opioid Receptor AntagonistKhanh Bui, Diansong Zhou, Hongmei Xu, et al.
Journal of Clinical Pharmacology|December 19, 2015
Effects of CYP3A Modulators on the Pharmacokinetics of NaloxegolKhanh Bui, Diansong Zhou, Mark Sostek, et al.
Cancer Chemotherapy and Pharmacology|April 26, 2019
Resistance models to EGFR inhibition and chemotherapy in non-small cell lung cancer via analysis of tumour size dynamicsHitesh B Mistry, Gabriel Helmlinger, Nidal Al-Huniti, et al.
British Journal of Clinical Pharmacology|August 29, 2015
Population pharmacokinetics of naloxegol in a population of 1247 healthy subjects and patientsNidal Al-Huniti, Sunny Chapel, Hongmei Xu, et al.
Journal of Clinical Pharmacology|December 2, 2017
Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive MetabolizersYingxue Chen, Diansong Zhou, Weifeng Tang, et al.
Journal of Clinical Pharmacology|December 3, 2015
Population Pharmacokinetic and Pharmacodynamic Modeling of AZD4901 and Simulation to Support Dose Selection for the Phase 2a StudyHongmei Xu, Jianguo Li, Lorraine Webber, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 29, 2021
Population pharmacokinetics and exposure-response modeling for evinacumab in homozygous familial hypercholesterolemiaXia Pu, Mark Sale, Feng Yang, et al.
Basic & Clinical Pharmacology & Toxicology|February 11, 2019
Physiologically based pharmacokinetic modelling to predict exposure differences in healthy volunteers and subjects with renal impairment: Ceftazidime case studyLi Zhou, Xiao Tong, Pradeep Sharma, et al.
Pharmaceutical Statistics|August 27, 2019
Optimal designs for regional bridging studies using the Bayesian power prior methodMario Nagase, Shinya Ueda, Mitsuo Higashimori, et al.
Pageof 6